COVID‐19‐related adrenal haemorrhage: Multicentre UK experience and systematic review of the literature

Objective Adrenal haemorrhage (AH) is an uncommon, usually incidental imaging finding in acutely unwell patients. AH has been reported during coronavirus disease 2019 (COVID‐19) infection and following ChAdOx1 nCoV‐19 (Oxford‐AstraZeneca) vaccination. The Society for Endocrinology (SfE) established a task force to describe the UK experience of COVID‐19‐related AH. Design A systematic literature review was undertaken. A survey was conducted through the SfE clinical membership to identify patients with COVID‐19‐related AH using a standardized data collection tool. Results The literature search yielded 25 cases of COVID‐19‐related AH (19 bilateral; 13 infection‐related, and 12 vaccine‐related). Eight UK centres responded to the survey with at least one case. A total of 18 cases were included in the descriptive study, including 11 from the survey and 7 UK‐based patients from the systematic review. Seven patients (4 males; median age 53 (range 26–70) years), had infection‐related AH (four bilateral). Median time from positive COVID‐19 test to AH detection was 8 (range 1–30) days. Eleven cases of vaccine‐related AH (eight bilateral) were captured (3 males; median age 47 (range 23–78) years). Median time between vaccination (nine Oxford‐AstraZeneca and two Pfizer‐BioNTech) and AH was 9 (range 2–27) days; 9/11 AH occurred after the first vaccine dose. Acute abdominal pain was the commonest presentation (72%) in AH of any cause. All 12 patients with bilateral AH and one patient with unilateral AH required glucocorticoid replacement. Conclusion Adrenal haemorrhage with consequential adrenal insufficiency can be a complication of COVID‐19 infection and vaccination. Adrenal function assessment is mandatory to avoid the potentially fatal consequences of unrecognized adrenal insufficiency.